Patents by Inventor Maurice Israel

Maurice Israel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process of authentication for an access to a web site
    Patent number: 9055061
    Abstract: A Process of reinforced authentication based on data collection of hardware components contained in a system having steps of enrolment authentication. A web site is connected to and a web page received. A list of hardware components is detected and collected. A subset of the list constituting digital information of reference (DDNA) is generated by a hash operation applied to the raw data. The DDNA is used with a received seed of an authentication server to generate a unique use password (OTP).
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: June 9, 2015
    Assignee: LoginPeople SA
    Inventor: Maurice Israel
  • Methods for treating glutamate cytotoxicity with beta-naphthoquinone compounds
    Patent number: 7572774
    Abstract: The present invention relates to the use of beta-naphthoquinone derivatives, and salts thereof, for the prevention and/or the treatment of glutamate cytotoxicity. It further relates to the use of beta-naphthoquinone derivatives, and salts thereof, for preventing and/or treating glutamate induced neurological disorders. Additionally, it concerns the use of beta-naphthoquinone derivatives, and salts thereof, for making drugs exerting an inhibitory effect on the release of glutamate.
    Type: Grant
    Filed: January 22, 2002
    Date of Patent: August 11, 2009
    Assignee: Centre National de la Recherche Scientific (C.N.R.S.)
    Inventors: Maurice Israel, Jordi Molgo, Christian Bloy, Cesar Mattei
  • Method of treating muscular dystrophies with an inhibitor of histone deacetylase
    Publication number: 20080160108
    Abstract: The present invention relates to the use of an inhibitor of histone deacetylase for preparing a drug for the treatment or prevention of a disease resulting from the deficiency of an adult gene in an individual by the re-expression of the homologous fetal gene. The invention concerns in particular the treatment of dystrophies such as Duchenne's dystrophy or Becker's dystrophy in which the defective adult gene is the dystrophin gene and the homologous fetal gene is the utrophin gene.
    Type: Application
    Filed: January 3, 2008
    Publication date: July 3, 2008
    Applicant: Centre National de la Recherche Scientifique- CNRS, a corporation of France
    Inventors: Sabine De La Porte, Maurice Israel, Vincent Voisin, Hafedh Haddad
  • Multitherapy Against Cancer
    Publication number: 20070280918
    Abstract: The invention concerns a pharmaceutical composition for treating cancer characterized in that it comprises a combination of a PP2A methylating agent and an active principle selected among the group consisting of a phosphatase PP1 inhibitor, a histone diacetylase inhibitor, a direct or indirect pyruvate kinase activator, a PTEN agonist, a tyrosine kinase inhibitor, a PI3 kinase inhibitor, a glucose competitor, a phosphocnol pyruvate carboxykinase inhibitor, a citrate synthase inhibitor and a latctate dehydro-genase inhibitor.
    Type: Application
    Filed: July 12, 2005
    Publication date: December 6, 2007
    Inventors: Laurent Schwartz, Maurice Israel
  • Method for identifying modulating compounds of neurotransmitters
    Patent number: 7279330
    Abstract: A process for identifying compounds that can modulate the release of neuromediators is described in which, for example, at least one compound that is to be tested is brought into contact with a nerve tissue preparation and the possible modulating effect of the compound on release of neuromediator by the nerve tissue preparation is determined. Methods of preparing calibrated pieces of mammalian cerebral material and kits for the implementation of the process are also described.
    Type: Grant
    Filed: August 10, 2000
    Date of Patent: October 9, 2007
    Assignee: Centre National de la Recherche Scientifique (C.N.R.S.)
    Inventors: Maurice Israël, Bernard Lesbats
  • Methods for the prevention and/or the treatment of glutamate cytotoxicity
    Publication number: 20070225236
    Abstract: The present invention relates to the use of beta-naphthoquinone derivatives, and salts thereof, for the prevention and/or the treatment of glutamate cytotoxicity. It further relates to the use of beta-naphthoquinone derivatives, and salts thereof, for preventing and/or treating glutamate induced neurological disorders. Additionally, it concerns the use of beta-naphthoquinone derivatives, and salts thereof, for making drugs exerting an inhibitory effect on the release of glutamate.
    Type: Application
    Filed: May 11, 2007
    Publication date: September 27, 2007
    Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIC (C.N.R.S.)
    Inventors: Maurice Israel, Jordi Molgo, Christian Bloy, Cesar Mattei
  • Methods for the prevention and/or the treatment of glutamate cytotoxicity
    Publication number: 20070225235
    Abstract: The present invention relates to the use of beta-naphthoquinone derivatives, and salts thereof, for the prevention and/or the treatment of glutamate cytotoxicity. It further relates to the use of beta-naphthoquinone derivatives, and salts thereof, for preventing and/or treating glutamate induced neurological disorders. Additionally, it concerns the use of beta-naphthoquinone derivatives, and salts thereof, for making drugs exerting an inhibitory effect on the release of glutamate.
    Type: Application
    Filed: May 11, 2007
    Publication date: September 27, 2007
    Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIC (C.N.R.S.)
    Inventors: Maurice Israel, Jordi Molgo, Christian Bloy, Cesar Mattei
  • Methods for the prevention and/or the treatment of glutamate cytotoxicity
    Publication number: 20070225237
    Abstract: The present invention relates to the use of beta-naphthoquinone derivatives, and salts thereof, for the prevention and /or the treatment of glutamate cytotoxicity. It further relates to the use of beta-naphthoquinone derivatives, and salts thereof, for preventing and/or treating glutamate induced neurological disorders. Additionally, it concerns the use of beta-naphthoquinone derivatives, and salts thereof, for making drugs exerting an inhibitory effect on the release of glutamate.
    Type: Application
    Filed: May 11, 2007
    Publication date: September 27, 2007
    Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIC (C.N.R.S.)
    Inventors: Maurice Israel, Jordi Molgo, Christian Bloy, Cesar Mattei
  • Use of a histone deacetylase inhibitor for treating muscular dystrophies
    Publication number: 20060148684
    Abstract: The invention relates to an inhibiter of histone deacetylase for treating or preventing a disease resulting from the deficiency of an adult gene in an individual by the re-expression of the homologous fetal gene. The invention concerns in particular the treatment of dystrophies such as Duchenne's dystrophy or Becker's dystrophy in which the defective adult gene is the dystrophin gene and the homologous fetal gene is the utrophin gene.
    Type: Application
    Filed: November 28, 2003
    Publication date: July 6, 2006
    Applicant: Centre National de la Recherche Scientifique-CNRS
    Inventors: Sabine De La Porte, Maurice Israel, Vincent Voisin, Hafedh Haddad
  • Composition and method for augmenting or restoring the production of fetal protein in patient in need thereof
    Patent number: 6872751
    Abstract: The present invention relates to methods for prevention and/or treatment of diseases or conditions caused by deficiency in the adult isoform of a given protein wherein said method comprises administering to a patient in need thereof a composition containing NO or at least one compound able to release, induce and/or promote NO formation in cells, said administration resulting in augmenting or restoring the production of the fetal isoform of said protein in said patient.
    Type: Grant
    Filed: April 29, 2002
    Date of Patent: March 29, 2005
    Assignee: Centre National de la Recherche Scientifique - CNRS
    Inventors: Maurice Israël, Sabine De La Porte, Philippe Fossier, Emmanuel Chaubourt, Gérard Baux, Christiane Leprince
  • Composition and method for augmenting or restoring the production of fetal protein in patient in need thereof
    Publication number: 20020164383
    Abstract: The present invention relates to methods for prevention and/or treatment of diseases or conditions caused by deficiency in the adult isoform of a given protein wherein said method comprises administering to a patient in need thereof a composition containing NO or at least one compound able to release, induce and/or promote NO formation in cells, said administration resulting in augmenting or restoring the production of the fetal isoform of said protein in said patient.
    Type: Application
    Filed: April 29, 2002
    Publication date: November 7, 2002
    Inventors: Maurice Israel, Sabine De La Porte, Philippe Fossier, Emmanuel Chaubourt, Gerard Baux, Christiane Leprince
  • Methods for the prevention and / or the treatment of glutamate cytotoxicity
    Publication number: 20020115617
    Abstract: The present invention relates to the use of beta-naphthoquinone derivatives, and salts thereof, for the prevention and/or the treatment of glutamate cytotoxicity. It further relates to the use of beta-naphthoquinone derivatives, and salts thereof, for preventing and/or treating glutamate induced neurological disorders. Additionally, it concerns the use of beta-naphthoguinone derivatives, and salts thereof, for making drugs exerting an inhibitory effect on the release of glutamate.
    Type: Application
    Filed: January 22, 2002
    Publication date: August 22, 2002
    Inventors: Maurice Israel, Jordi Molgo, Christian Bloy, Cesar Mattei
  • Use of N-(1-hexahydroazepinylalkyl) acetamides for the treatment of cholinergic transmission disorders
    Patent number: 5200405
    Abstract: The invention relates to the use of a compound selected from those of formula (I): ##STR1## in which R, R.sub.1, R.sub.2 and n are as defined in the description, for the treatment of cholinergic transmission disorders.
    Type: Grant
    Filed: September 11, 1991
    Date of Patent: April 6, 1993
    Assignee: Adir et Compagnie
    Inventors: Maurice Israel, Yvette Morot-Gaudry, Max Robba, Gerard Adam, Pierre Renard